All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
-
- Talmadge E. King
- University of California, San Francisco, California
-
- Carlo Albera
- University of Turin, Turin, Italy
-
- Williamson Z. Bradford
- InterMune Inc., Brisbane, California
-
- Ulrich Costabel
- Ruhrlandklinik, Essen, Germany
-
- Roland M. du Bois
- Imperial College, London, United Kingdom
-
- Jonathan A. Leff
- InterMune Inc., Brisbane, California
-
- Steven D. Nathan
- Inova Fairfax Hospital, Falls Church, Virginia
-
- Steven A. Sahn
- Medical University of South Carolina, Charleston, South Carolina
-
- Dominique Valeyre
- Assistance Publique-Hôpitaux de Paris, Avicenne University Hospital, Bobigny, France; and
-
- Paul W. Noble
- Cedars Sinai Medical Center, Los Angeles, California
収録刊行物
-
- American Journal of Respiratory and Critical Care Medicine
-
American Journal of Respiratory and Critical Care Medicine 189 (7), 825-831, 2014-04-01
American Thoracic Society
